Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Asciminib Drug Analysis 2016-2025: A BCR-ABL-Targeted Tyrosine Kinase Inhibitor (TKI) in Development by Novartis -

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: asciminib" drug pipelines has been added to's offering.

Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) in development by Novartis for Philadelphia chromosome-positive diseases such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia. Unlike the first- and second-generation TKIs currently approved for CML, which target the catalytic site of ABL, asciminib targets the myristoyl pocket of ABL, allowing it to be effective in patients previously treated with other TKIs.

Furthermore, asciminib's ability to bind to an alternative site may allow the drug to be used in combination with another TKI, an approach which could be effective against a broad range of secondary mutations.

As Gleevec (imatinib; Novartis) remains the standard of care for first-line CML patients, and Tasigna's (nilotinib; Novartis) primary role has been restricted to second-line patients, Novartis will develop asciminib for the third-line setting in order to avoid sales cannibalization and to bolster its CML franchise following the generic incursion of Gleevec.

Asciminib is being tested head-to-head versus Bosulif (bosutinib; Pfizer) in a pivotal Phase III trial. While the exclusion criteria of this trial may prevent asciminib's use in patients with specific secondary mutations, the drug has the potential to be more effective in combination with another TKI, which could provide previously treated patients with secondary mutations with an important alternative treatment option.

Key Topics Covered:

List of Figures

Figure 1: Asciminib for CML - SWOT analysis

Figure 2: Drug assessment summary of asciminib for CML

Figure 3: Drug assessment summary of asciminib for CML

List of Tables

Table 1: Asciminib drug profile

Table 2: Asciminib Phase III trial in CML

Table 3: Asciminib early-phase trial data in CML

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.